CRYOMAREX RISPENS, solution for injection

Boehringer Ing. Pharma GmbH & Co. KG

Revision date : 2022-02-28

SDS Library

Move your SDS library online today

Check Icon
Setup – Easy setup with our database of 16 million+ SDSs
Check Icon
Up-to-date – Your SDS get updated to latest versions.
Check Icon
Employee access – Tablets, Smartphones, or link from Corporate Intranet
Check Icon
Safety – One-click access to first aid information.
Check Icon
Labels – Generate Secondary Container Labels with just one click.
Health risk rating 1
Safety risk rating 1
Environmental risk rating 1

General Information

Version

2.1

Revision date

2022-02-28

Product name

CRYOMAREX RISPENS, solution for injection

Product Synonyms

Marek’s Disease Vaccine, Serotype 1, Live Virus; Rispens®

1.2.1 Relevant identified uses

Veterinary product

1.2.2. Uses advised against

Safety Data Sheet only for the professional user., For veteri- on use nary use only, Refer to the product insert for complete instruc- tions on usage

Emergency telephone

+498007790900, +1 703-527-3887, +49800 1817059

Icons in SDS

M004 M009 M010 M011 M017 M059

Company Information

company name

Boehringer Ing. Pharma GmbH & Co. KG

e-mail address of the competent person responsible for the Safety Data Sheet

EHS-Services@Boehringer-Ingelheim.com

Section 2

SECTION 2: Hazards identification

Regulation (EC) No. 1272/2008 Classification of the substance or mixture

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumula- tive and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

ECOLOGICAL INFORMATION

The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regu- lation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

TOXICOLOGICAL INFORMATION

The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher. This drug is not subject to the labelling requirements under the Globally Harmonized System (GHS) The pharmacological effect of the medicament has to be considered (see package leaflet). In case the product is handled, stored or shipped with dry ice or liquid nitrogen, please consider the respective SDS.

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008) Not a hazardous substance or mixture.

SDS Library

Move your SDS library online today

Check Icon
Setup – Easy setup with our database of 16 million+ SDSs
Check Icon
Up-to-date – Your SDS get updated to latest versions.
Check Icon
Employee access – Tablets, Smartphones, or link from Corporate Intranet
Check Icon
Safety – One-click access to first aid information.
Check Icon
Labels – Generate Secondary Container Labels with just one click.